Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Distribution of WCD use days in WEARIT-II

Published byAlessia Masi Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Distribution of WCD use days in WEARIT-II"— Presentation transcript:

1 Figure 1 Distribution of WCD use days in WEARIT-II
Figure 1 Distribution of WCD use days in WEARIT-II. WCD, wearable cardioverter-defibrillator. Figure 1 Distribution of WCD use days in WEARIT-II. WCD, wearable cardioverter-defibrillator. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Europace, Volume 20, Issue FI2, 14 June 2018, Pages f225–f232, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 Clinical outcomes at the end of WCD use by duration of WCD use. *P < 0.001 for end of use category for ... Figure 2 Clinical outcomes at the end of WCD use by duration of WCD use. *P < 0.001 for end of use category for patients with ≤90 days of total wear vs. >90 days of total wear. EF, ejection fraction; ICD, received implantable cardioverter-defibrillator; WCD, wearable cardioverter-defibrillator. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Europace, Volume 20, Issue FI2, 14 June 2018, Pages f225–f232, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 Clinical outcomes at the end of WCD use by the duration of WCD use and by disease aetiology. *P-value < Figure 3 Clinical outcomes at the end of WCD use by the duration of WCD use and by disease aetiology. *P-value <0.001 for ≤90 vs. >90 total days wear time. <sup>†</sup>P-value <0.001 in the ≤90 days wear time group for EOU by disease aetiology. C/I, congenital or inherited heart disease; EF, ejection fraction; EOU, end of use; ICD, implantable cardioverter-defibrillator; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic cardiomyopathy; WCD, wearable cardioverter-defibrillator. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Europace, Volume 20, Issue FI2, 14 June 2018, Pages f225–f232, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Distribution of WCD use days in WEARIT-II"

Similar presentations

J Exp Bot. 2017;68(17): doi: /jxb/erx352

J Exp Bot. 2017;68(17): doi: /jxb/erx352
Figure 1 Study flow chart.

Figure 1 Study flow chart.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Figure 1 The study area within Vienna Zoo is outlined in red

Figure 1 The study area within Vienna Zoo is outlined in red
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1 The process of bone defect creation, implant insertion and ridge augmentation. (a) Creation of standardized ... Figure 1 The process of bone defect.

Figure 1 The process of bone defect creation, implant insertion and ridge augmentation. (a) Creation of standardized ... Figure 1 The process of bone defect.
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1. Comparison of weighted estimates of diarrhoea prevalence in children under five by country between PMA2020 ... Figure 1. Comparison of weighted.

Figure 1. Comparison of weighted estimates of diarrhoea prevalence in children under five by country between PMA Figure 1. Comparison of weighted.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Similar presentations

Ads by Google